Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2022-03-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于使用部分闲置自有资金进行理财管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company regarding the use of idle funds for financial management, including details about the investment products, risk control measures, and approvals by the board and supervisory committee. It does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a financing-related decision but not a full capital or financing update report. Given the nature of the announcement about the use of funds and the approval process, it fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2022-03-30 Chinese
中德证券有限责任公司关于启迪药业集团股份公司使用闲置募集资金购买保本理财的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsoring institution (中德证券有限责任公司) regarding the use of part of idle raised funds by 启迪药业集团股份公司 to purchase principal-guaranteed financial products. It references regulatory guidelines on the management and use of raised funds, details the fundraising amount, usage, idle reasons, investment purpose, risk control measures, and approval procedures. The document is not a financial report like an annual or interim report, nor is it a simple announcement. It is a formal verification opinion related to the use of raised funds, which aligns with a Capital/Financing Update (CAP) category, as it concerns fundraising usage and capital management updates. The document length (5167 characters) and content confirm it is a substantive report rather than a brief announcement or certification. Therefore, the best fitting classification is Capital/Financing Update (CAP).
2022-03-30 Chinese
独立董事关于第九届董事会第五次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a pre-approval opinion from independent directors regarding agenda items for the company's ninth board meeting, including approval of daily related-party transactions and appointment of the 2022 audit firm. It does not contain financial statements or detailed financial data, nor is it a full audit report or annual report. It is related to board meeting matters and approvals. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2022-03-30 Chinese
独立董事对担保等事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent directors' opinion report on various company matters including internal control evaluation, use of raised funds, profit distribution, appointment of auditors, and a stock incentive plan. It references compliance with regulatory guidelines and company governance rules. The document is a formal opinion statement by independent directors rather than a full financial report or earnings release. It does not contain financial statements or detailed financial data but provides independent opinions on specific corporate governance and financial management issues. The document length is 3631 characters, which is relatively short and focused on governance and compliance opinions. This fits best with the category of Board/Management Information (MANG), as it relates to board opinions and governance matters rather than a full annual report or audit report. It is not a report publication announcement or regulatory filing since it contains substantive independent opinions rather than just an announcement or certification.
2022-03-30 Chinese
年度募集资金使用鉴证报告
Regulatory Filings
2022-03-30 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 9th Board of Directors meeting of Qidi Pharmaceutical Group Co., Ltd. It includes approvals of the 2021 Annual Report, Board Work Report, Financial Statements, Profit Distribution Plan, Internal Control Evaluation Report, and other related reports. It also discusses proposals related to the 2022 restricted stock incentive plan and other corporate governance matters. The document references the full 2021 Annual Report and other reports being published separately on external websites (e.g., cninfo.com.cn) and newspapers, indicating this document itself is not the full annual report but a board meeting resolution announcement. The document length is about 5388 characters, which is relatively short and mainly summarizes decisions and approvals rather than containing full financial statements or detailed report content. Therefore, this document is best classified as a Board/Management Information (MANG) filing, as it announces board meeting resolutions and management decisions rather than the full annual report or audit report itself.
2022-03-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.